Samsung Biologics Signs MOU with Sartorius to Enhance Supply Chain for Biomedicines

Article

The agreement follows a recent announcement that Sartorius plans to invest $100 million in Songdo, South Korea’s bio cluster.

Samsung Biologics has signed a memorandum of understanding (MOU) with Sartorius to further strengthen the supply chain for biomedicines. The MOU follows a recent announcement by Sartorius that the company plans to invest $100 million in South Korea's bio cluster, Songdo, to build a bioprocess manufacturing facility for equipment and materials, Samsung Biologics announced in a Nov. 16, 2020 press release.

Sartorius plans to supply materials such as disposable bags, cell culture media, and filters to Samsung Biologics. The facility will be built on a 24,333-m2 site in Songdo. Construction is expected to be completed by 2022.

Source: Samsung Biologics

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!
Recent Videos
DC skyline at night with view of the White House and the Washington Monument | Image Credit: © Jessica - stock.adobe.com
Related Content
Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

AATec Medical and Northway Biotech Partner to Develop Lung Disease Therapy

Susan Haigney
July 15th 2025
Article

Northway Biotech will develop and scale production of AATec’s ATL-105 for the treatment of non-CF bronchiectasis.

Podcast: Alternative Drug Delivery Methods for Biologics: Where Are We At?

Podcast: Alternative Drug Delivery Methods for Biologics: Where Are We At?

Feliza Mirasol
September 27th 2024
Podcast

This podcast explores the challenges of and the progress made so far by the biopharma industry toward alternative drug delivering methods for biologic drugs.

Thornhill, Ontario, Canada - October 31, 2020: LEO Pharma Canada sign outside their head office building in Thornhill, Ontario, Canada. LEO Pharma AS is a multinational Danish pharmaceutical company | Image Credit: © JHVEPhoto - stock.adobe.com.

LEO Pharma Takes Over Global Development of Spevigo for Rare Skin Disease GPP

Christopher Cole
July 14th 2025
Article

The IL-36 inhibitor is being explored for additional inflammatory skin conditions, aiming to expand treatment options for underserved patient groups.

Drug Solutions Podcast: Considering Biologic Drug Development and Manufacturing Holistically

Drug Solutions Podcast: Considering Biologic Drug Development and Manufacturing Holistically

Felicity Thomas
May 25th 2023
Podcast

Hanns-Christian Mahler and Andrea Allmendinger from ten23 health will discuss some key aspects of biologic drug development and manufacturing.

low angle view of marble dome of United States Capitol building in Washington DC with blue sky and visible architecture features | Image Credit: © Philip - stock.adobe.com.

9 Implications of Trump’s Tax-Cut and Spending Bill for the Bio/Pharmaceutical Industry

Christopher Cole
July 7th 2025
Article

Trump’s tax bill could reshape drug R&D, manufacturing, Medicaid access, clinical trials, and biotech funding, impacting strategy across the bio/pharmaceutical industry.

Messenger RNA or mRNA strand 3D rendering illustration with copy space. Genetics, science, medical research, genome replication concepts | Image Credit: © Matthieu - stock.adobe.com

5 Ways mRNA Is Revolutionizing Drug Development Beyond Vaccines

Christopher Cole
July 2nd 2025
Article

Once limited to experimental vaccine platforms, messenger RNA (mRNA) is now taking center stage across the entire biotech landscape.

© 2025 MJH Life Sciences

All rights reserved.